Abstract CT255: EATON: A phase I dose-escalation trial of nazartinib (EGF816) and trametinib in EGFR-mutant NSCLC

Authors: Sebastian Michels, Lucia Nogova, Matthias Scheffler, Barbara Deschler-Baier, Martin Sebastian, Martin Schuler, Martin Wermke, Enriqueta Felip, Rafael Rosell, Delvys Rodriguez Abreu, Diana S.Y. Abdulla, Rieke N. Fischer, Sophia Koleczko, Anna Kron, Richard Riedel, Jan-Philipp Weber, Jana Fassunke, Sabine Merkelbach-Bruse, Heinz Haverkammp, Martin Hellmich, Reinhard Büttner, Jürgen Wolf,

Published: 2020-09-04

DOI: 10.1158/1538-7445.am2020-ct255

Source: Full article